About Vernalis Research

Picture1Vernalis Research is 65 experienced staff based in Granta Park, Cambridge, UK. Our strength is solving problems in drug discovery. This expertise has generated 6 development candidates in the past 5 years and successfully identified cell-active lead compounds for more than 13 other targets.

Our business model is to balance an internal portfolio of drug discovery projects with full collaborations on targets with pharmaceutical partners such as Genentech, Asahi Kasei Pharma, GSK, Lundbeck and Servier. We aim to establish additional collaborations during 2014 / 15

Our distinctive approach is to integrate the most appropriate methods in biophysics, protein structure and molecular modelling with medicinal chemistry. In addition, we have the experience and capabilities for progressing projects from target identification through to clinical candidate. The internal projects at Vernalis are in oncology and anti-infectives; our collaborations are across all therapeutic areas - currently oncology, neurodegeneration, anti-infectives and inflammation.

Latest News

Vernalis plc receives a $2 million milestone payment from one of its drug discovery collaborations

Vernalis plc announced today that it has received a $2m milestone under one of its existing research collaborations to discover novel small molecules against an undisclosed target utilising Vernalis' fragment and structure-based drug discovery platform.

Read more ...

Product Pipeline

For more information on our pipeline, click below to visit Vernalis plc

Commercial Pipeline

Comm-thumbnailExplore the pipeline ...

 

NCE Pipeline

NCE-thumbnailExplore the pipeline ...

 

Contact Vernalis Research

T: (0)1223 895555
F: (0)1223 895556

Contact information
Maps and directions
Contact form

Fact Sheet

For more information on Vernalis, click on the below image to download a copy of our fact sheet

Vernalis Factsheet May 2015 Page 1